VVT Medical receives approval for its ScleroSafe platform by the Korean Ministry of Food and Drug Safety.

Kfar Saba, Israel – April 25, 2024 – V.V.T. Med Ltd. (“VVT Medical”), a global leader in medical devices, proudly announces the completion of GMP certification and registration of Novel Non-Thermal, Anesthesia- free treatment for Varicose veins. This milestone approval adds to the recent FDA 510(k) clearance and existing CE Mark, reinforcing ScleroSafe™’s position as a trusted solution with regulatory approvals worldwide.

The approval of ScleroSafe™ by the Ministry of Food and Drug Safety (MFDS) marks a significant achievement for VVT Medical in the Korean market. With the demand for innovative medical solutions on the rise in Korea, ScleroSafe™ offers a unique, painless, and anesthesia-free treatment option that aligns perfectly with the country’s growing preference for minimally invasive procedures to treat varicose veins.

“We are delighted to receive approval from the MFDS for ScleroSafe™,” said Erez Tetro CEO of VVT Medical. “This endorsement underscores our commitment to providing cutting-edge technologies that improve patient outcomes and set new standards in vascular treatments.”

VVT Medical aims to strategically collaborate with leading Korean healthcare professionals to introduce ScleroSafe™ and drive advancements in vascular care across Korea. Through these partnerships, VVT Medical seeks to improve access to advanced treatment options and elevate the standard of patient care nationwide.

The launch of ScleroSafe™ in Korea signifies a significant stride in VVT Medical’s global expansion strategy, reinforcing the company’s position as a pivotal player in the medical device industry. With a focus on addressing the needs of tens of millions of varicose vein patients worldwide, VVT Medical continues to prioritize innovation and excellence in healthcare.